Compare Baxter International Inc (BAX) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Marvell Technology Inc — how do they compare? Baxter International Inc trades at $27.08 (market cap $14.27B), while Marvell Technology Inc trades at $222.1 (market cap $190.56B). The key difference: Marvell Technology Inc is far larger — about 13.4× Baxter International Inc's market cap, and Baxter International Inc pays the higher dividend (0.14%). Which is the better fit depends on your goals.
| BAX | MRVL | |
|---|---|---|
Market Cap | $14.27B | $190.56B |
Sector | Health | Technology |
52-Week High | $28.35 | $316.43 |
52-Week Low | $15.80 | $62.31 |
Enterprise Value | $21.79B | $191.99B |
Dividend Yield | 0.14% | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International Inc. (BAX) trades at $27.78, up 0.83% today, with a bullish technical outlook supported by moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.56 versus $0.37 expected, and revenue guidance was raised, signaling operational improvement. However, the company posted a net loss of -$957 million in 2025, with negative profit margins and high P/E of 87.85, reflecting valuation concerns amid turnaround efforts.
The stock shows potential from earnings momentum and cost initiatives, but high debt and inconsistent profitability pose risks. Analyst consensus is mixed with a $25.43 price target below current levels, suggesting cautious optimism. Investors should weigh recent beats against structural challenges in the medtech sector.
Marvell Technology (MRVL) trades at $221.15, up 6.04% today, reflecting strong momentum amid AI-driven optimism. The stock exhibits a bullish technical signal with moving averages supporting the uptrend, while recent earnings beats and a consensus analyst price target of $275.68 highlight fundamental strength. Key developments include partnerships with NVIDIA and Microsoft's Maia 300 AI accelerator, positioning MRVL for growth in data center and networking segments.
Outlook remains positive with AI infrastructure expansion driving revenue projections to $8.7B in 2026, though high valuation ratios (P/E 72.96) and supply chain risks warrant caution. Net income turned profitable in 2026 forecasts, but competitive pressures and market volatility pose challenges. Analyst consensus is strongly bullish with 82% buy ratings, suggesting upside potential if execution aligns with growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
